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Abstract
A mechanism-based biomarker model of TNFa-response, including different external provocations of LPS challenge and
test compound intervention, was developed. The model contained system properties (such as kt, kout), challenge charac-
teristics (such as ks, kLPS, Km, LPS, Smax, SC50) and test-compound-related parameters (Imax, IC50). The exposure to test
compound was modelled by means of first-order input and Michaelis–Menten type of nonlinear elimination. Test com-
pound potency was estimated to 20 nM with a 70% partial reduction in TNFa-response at the highest dose of 30 mgkg-1.
Future selection of drug candidates may focus the estimation on potency and efficacy by applying the selected structure
consisting of TNFa system and LPS challenge characteristics. A related aim was to demonstrate how an exploratory
(graphical) analysis may guide us to a tentative model structure, which enables us to better understand target biology. The
analysis demonstrated how to tackle a biomarker with a baseline below the limit of detection. Repeated LPS-challenges
may also reveal how the rate and extent of replenishment of TNFa pools occur. Lack of LPS exposure-time courses was
solved by including a biophase model, with the underlying assumption that TNFa-response time courses, as such, contain
kinetic information. A transduction type of model with non-linear stimulation of TNFa release was finally selected. Typical
features of a challenge experiment were shown by means of model simulations. Experimental shortcomings of present and
published designs are identified and discussed. The final model coupled to suggested guidance rules may serve as a general
basis for the collection and analysis of pharmacological challenge data of future studies.
Keywords Target biology  Kinetic-dynamic modelling  Challenge tests  Experimental design  Non-linear mixed effects
modelling
Introduction
Tumour necrosis factor alpha (TNFa) is a pro-inflammatory
cytokine associated with the pathogenesis of several
immune-mediated diseases, such as rheumatoid arthritis
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and Crohn disease [1]. Since TNFa release is a typical
response to a variety of inflammatory mediators, it became
an important biomarker for various diseases mediated by
inflammation [2]. Free TNFa is almost undetectable in
blood of healthy organisms. However, pro-inflammatory
challengers can induce TNFa expression and release of
soluble TNFa after proteolytic cleavage of a precursor
molecule by TNFa-converting enzyme TACE/ADAM-17
[7]. Experimentally, the effect of the inflammatory medi-
ators is studied in vitro in whole blood assays or in vivo
after intravenous administration of lipopolysaccharides
LPS, where the challenger causes a rapid but transient
release of TNFa [3, 6]. The in vivo LPS-challenge models
are commonly utilized in drug discovery to identify and
characterize anti-inflammatory drugs [4, 5]. However,
experimental design will have a great impact on the results,
particularly for drug-related pharmacodynamic parameters
such as potency and efficacy [6]. In a typical in vivo LPS
challenge experiment, only TNFa and test-compound
concentrations are measured over time after a single LPS
dose. The fact that the exposure to LPS concentrations is
difficult to quantify causes a modelling problem. The
question arises of how to define the stimulatory input of
TNFa-response. Therefore, some of the current models use
an LPS-stimulated biophase input [6].
Several models of LPS-induced TNFa-response have been
proposed, including, to name just the most recent: (1) linearly
stimulated turnover in combination with a series of transit
compartments [6]; (2) a lag-time approach to pre-cursor-de-
termined TNFa production [10, 12, 24]; (3) soluble TNFawith
a time-dependent turnover rate [11, 12, 25]; (4) a quadratic
function forTNFaproduction [26]; (5) an inhibitory Imaxmodel
of TNFa [27]; (6) a nonlinear FAA-driven stimulatory model
with lag-time [28]. All of thesemodels lack to a varying extent
a quantitative description of delayed onset, saturable intensity
and extended duration of LPS-induced TNFa-response fol-
lowing several dose levels of both LPS and test compound.
Three different LPS challenges (Study 1) and three
inhibitory test-compound doses (Study 2) are investigated
from a macro-pharmacological perspective using TNFa-
response as a biomarker of target behavior (Fig. 1). Test-
compound A is a selective inhibitor of phosphodiesterase
(PDE) type 4 isoforms. The PDE4 isoforms have been
shown to be involved in the LPS-induced TNFa release
using genetic knockouts, and with the marketed pan-PDE4
inhibitors apremilast and roflumilast [30, 31].
The goal was therefore to identify the determinants of
target biology related to TNFa turnover by means of pooling
data from two preclinical studies in rats. This was done in
order to answer the question: Will multiple LPS and test-
compound provocations help in simultaneously character-
izing TNFa system behavior, LPS challenge characteristics
and test-compound properties, as suggested earlier. The
analysis was tailored to derive a kinetic-dynamic model of
TNFa-response, which has potential in discovery data anal-
yses. Therefore, a meta-analysis was performed on available
data from two separate studies on TNFa-response after
multiple LPS and test compound interventions. For this
purpose, a mixed-effects approach was a useful tool. Typi-
cally, if an accurate and precise estimate of the pharmaco-
dynamic properties of a test compound is sought, time-series
analyses of challenger- and biomarker-time data are neces-
sary. Erosion of data, resulting in the single-point assessment
of drug action after a challenge test, should be avoided. This
is particularly relevant for situationswhere one expects time-
curve shifts, functional adaptation, impact of disease, or
hormetic concentration-response relationships to occur [6].
Materials and methods
Chemicals
Lipopolysaccharides (LPS) from Escherichia coli 0111:B4
was obtained from Sigma (Product number L4391; the same
batch 036M4070V was used for both studies). The test-com-
pound A was synthesized at Grunenthal, Aachen, Germany,
and the purity of the batch used in this study wasC 95%. The
physico-chemical properties of test compound A are pre-
sented in Table 1. Test-compound A was developed as an
inhibitor of PDE4. The rat TNFa Quantikine ELISA kit was
purchased from R&D systems (SRTA00, Batches P143557,
P118837, and 339837).All other reagents and chemicals were
of analytical grade and were obtained from standard vendors.
Animals
The studies were conducted in male Sprague–Dawley rats,
approximately 210–260 g of body weight, purchased from
Vital River Laboratory Animals Co. LTD. All rats were
housed in groups under 12 h light/dark cycle with ad libi-
tum access to food and water. During the study, animals
were not fasted, but no food was provided prior to dosing
until 3 h after drug dosing. All animals were handled in
strict accordance with the Guide for the Care and Use of
Laboratory Animals in an AAALAC-accredited facility.
All animal studies were approved by an established Insti-
tutional Animal Care and Use Committee (IACUC).
Design of in vivo studies
LPS was dissolved in saline at 0.0006, 0.006, and
0.06 mgmL-1 and 5 mLkg-1 of the solutions were dosed
intravenously via foot dorsal vein injection to give doses of
3, 30 and 300 lgkg-1, respectively. Test-compound A
was suspended in 1% HPMC (5 mPa s, Colorcon) and
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0.5% Tween 80 (Sigma) in water at concentrations of 0.06,
0.6, and 6 mgmL-1. Test-compound A was administered
at a volume of 5 mLkg-1 by oral gavage, resulting in
doses of 0.3, 3 and 30 mgkg-1, respectively.
Forty-eight normal male Sprague–Dawley rats were
used in the LPS-induced TNFa-response model in the
absence (Study 1) or presence (Study 2) of test-compound
A (Fig. 1). The animals were randomly divided into eight
groups (n = 6). In Study 1, four groups of animals were
given increasing intravenous doses of LPS (0, 3, 30 and
300 lgkg-1 LPS). In Study 2, four groups of animals
received a fixed intravenous dose of LPS challenger of
30 lgkg-1 and increasing oral doses of test compound (0,
0.3, 3 and 30 mgkg-1 compound A). Test compound was
administered two hours before the challenge with LPS.
Blood samples were drawn for quantification of Test-
compound A and TNFa before dosing of test compound (at
- 2 h) and at - 1, 0, 0.5, 1, 1.5, 2, 3, and 4 h after LPS
dosing (Fig. 2). Blood samples were collected into EDTA-
2K tubes via tail vein or cardiac puncture for terminal
bleeding. Samples were stored on ice and centrifuged at
20009g for 5 min at 4 C within 15 min after sampling.
Each plasma sample was divided into two aliquots, one for
LC-MS/MS analysis to measure test compound concen-
trations, and one for ELISA analysis to measure the bio-
marker TNFa concentrations. Until quantification, the
plasma samples were stored at -70 C after snap-freezing
of plasma in dry ice.
Table 2 summarizes the experimental design of the two
studies. Study 1 was conducted to characterize the dose-
response-time relationships of the TNFa-release after LPS
challenge and to define an appropriate LPS challenge dose.
Study 2 investigated the inhibition of this response by Test-
compound A using a fixed LPS challenge dose and three
inhibitory test-compound doses. Full response time courses
for TNFa were obtained and analyzed by modelling. The
test-compound concentrations over time were measured as
well, but the actual exposure to LPS could not be quantified
due to the nature of LPS, which consists of a poorly defined
mixture of different components of the bacterial cell wall.
Fig. 1 Schematic presentation of the two studies incorporated into the
analysis. Upper row: three LPS challenge doses (3, 30 and
300 lgkg-1 of LPS) were given in Study 1 and the TNFa-response
was measured. No time courses are available for LPS. Bottom row:
the middle challenge dose (30 lgkg-1 of LPS) was selected for three
groups of rats that received 0.3, 3 and 30 mgkg-1 of test-compound
A in Study 2
Table 1 Physico-chemical properties of compound A
Parameter Value
Molecular weight \ 500 gmol-1
cLogP \ 2.5
PSA \ 80 A˚2
Solubility [ 10 lmolL-1 at pH 7.4
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Bioanalytical methods
Quantification of TNFa concentrations by ELISA
TNFa concentrations in plasma were quantified with the rat
TNFa Quantikine ELISA Kit (R&D Systems, SRTA00)
according to the instructions provided in the kit, using
seven calibrations standards ranging from 12.5 to
800 ngL-1. The measured concentrations of the quality
controls were all in the range as specified in the kit
instruction and showed CV %\ 20%. The lower limit of
quantification (LLOQ) was 12.5 ngL-1 and lower values
were reported as ‘‘\LLOQ’’ and excluded from subsequent
evaluation and parameter estimation.
Quantification of test-compound A concentrations by LC-
MS/MS
For the quantification of the test compound, acetonitrile
which contained dexamethasone as internal standard was
added to plasma prepared from the blood samples for
protein precipitation. Supernatants were injected onto a
C18 reversed phase column for LC-MS/MS analysis. The
UPLC separation was carried out using a gradient elution
in H2O containing 0.025% formic acid/1 mM NH4OAc
(mobile phase A) and methanol that contained 0.025%
formic acid/1 mM NH4OAc (mobile phase B). The ana-
lytes were quantified on an API5500 mass spectrometer
using multiple reaction monitoring with appropriate mass
transitions. Each set of samples was run together with two
calibration sets containing nine non-zero standard con-
centrations covering a range of range from 1 to 3000 nM.
Quality controls of 3, 500, and 2400 nM were interspersed
between the samples. The calculated concentrations of the
calibration samples and quality controls were within ±
15% of the nominal values (20% at LLOQ) for at least 75%
and 67% of the samples, respectively. Concentrations
below 80% of the LLOQ (i.e. below 0.8 nM) were reported
as ‘‘\LLOQ’’ and excluded from subsequent evaluation
and parameter estimation.
Pharmacokinetic and pharmacodynamic models
Test compound kinetics
The impact of test compound on the TNFa-response is
shown conceptually in Fig. 3a and b. The first-order loss of
test compound from the gut is given by Eq. 1.
dAab
dt
¼  kaAab ð1Þ
The plasma exposure to test compound was then
described by a one-compartment model with first-order
oral input and Michaelis–Menten elimination.
Vp  dCp
dt
¼ F  ka  Aab  Vmax  Cp
Km þ Cp ð2Þ
Aab denotes amount of test compound in the gut, Cp
exposure to drug in plasma, ka the first-order absorption
rate constant, Vmax maximum rate of elimination, Km the
Fig. 2 Schematic presentation of the designs of Study 1 and 2.
Arrows denote time of test-compound and LPS administration. Blood
droplets denote harvesting of plasma samples for assessment of test-
compound concentrations and TNFa-response, respectively. Test
compound was only administered in Study 2 and no blood sample
at - 1 h was taken in Study 1
Table 2 Overview of experimental designs of the two individual studies
Study Challenge
compound
Animal
model
Test-
compound
PD effect
biomarker
Designs
1 LPS Rat – TNFa Three LPS challenge doses (3, 30 and 300 lgkg-1); lacks challenger time
course(s); no drug intervention
2 LPS Rat A TNFa One LPS challenge dose (30 lgkg-1); lacks challenger time course(s); three test-
compound intervention doses (0.3, 3 and 30 mgkg-1)
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Michaelis–Menten constant, and Vp volume of distribution.
The bioavailability F was set to unity.
LPS challenge model
The impact of the LPS challenge on the TNFa-response is
shown conceptually in Fig. 3b and c. The intravenous LPS
dose is injected into plasma as a bolus and cleared from
plasma via first-order elimination.
dALPS
dt
¼  kLPSALPS ð3Þ
The level of LPS in plasma triggers a series of trans-
duction compartments with a saturable process ALPS /
(Km, LPS ? ALPS). The S3 signal acts on the build-up of
TNFa-response via stimulatory action (S(S)3). The trans-
duction of LPS-induced signal from S1 through S3 is given
by Eq. 4.
ds1
dt
¼ ks  ALPS
Km; LPS þ ALPS  S1
 
ds2
dt
¼ ks  S1  S2ð Þ
ds3
dt
¼ ks  S2  S3ð Þ
ð4Þ
ALPS is LPS amount in the biophase and S1 to S3 are a chain
of transduction compartments which act as signaling
compartments. LPS is thought to be eliminated with rate
constant kLPS. Signal S1 is stimulated non-linearly by LPS
with Michaelis–Menten constant Km. Rate constant ks
describes transfer of signal across S1 to S3 and loss from
system.
TNFa turnover model
Figure 3b shows conceptually the TNFa turnover R and the
impact of both the LPS challenge and the test compound
kinetics on the TNFa-response. The dynamics of TNFa-
Fig. 3 Schematic presentation of the kinetic and dynamic model.
Solid lines symbolize mass transfer and dashed lines stand for control
streams. Upper row A: Kinetic model of test compound disposition
after oral administration. Here, Aab and Cp denote, respectively,
amount and concentration in the gut and central plasma compartment.
The volume of the latter is denoted by Vp. F and ka are the
bioavailability and the absorption rate of the test compound. Vmax and
Km are the maximum elimination and Michaelis–Menten constant.
Middle row B: Turnover model for the TNFa-response. TNFa is
divided into compartments R and Rt. Here, kt and kout denote the first-
order transfer rate between compartments and elimination rate from
the system. TNFa turnover is stimulated by LPS challenge from part
C and inhibited by test compound kinetics from part A. Here, Imax is
maximum inhibitory capacity of the test-compound and IC50 its
potency, Smax is maximum stimulatory capacity, c is a Hill exponent
and SC50 is the potency of LPS challenge. Bottom row C: Model of
LPS challenge. A first-order biophase ALPS describes LPS after
intravenous administration with first-order elimination rate kLPS. LPS
non-linearly stimulates a signal chain (S1 to S3) with Michaelis–
Menten constant Km, and signal transfer—as well as elimination rate
ks. A more detailed description of the principal parts of the model and
their behavior are discussed in appendix
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response is divided into a central R and a peripheral Rt pool
governed by a first-order inter-compartmental rate constant
kt, in order to capture the post-peak bi-phasic decline of
response. The irreversible loss of TNFa occurs from its
central compartment via a first-order rate process kout R.
The stimulatory action via S3 of LPS-induced challenge
is given by Eq. 5.
S S3ð Þ ¼ Smax  S
c
3
SC
c
50 þ Sc3
ð5Þ
Smax is the maximum LPS stimulatory production rate of
TNFa, and SC50 is the corresponding transducer concen-
tration S3 where 50% of maximum rate occurs. The inhi-
bitory action of test compound I(Cp) on build-up of
response is.
IðCpÞ ¼ 1 Imax  Cp
IC50 þ Cp ð6Þ
The structure of Eq. 6 allows a partial Imax inhibitory
effect of the test compound. The IC50 parameter denotes
the concentration of test compound resulting in 50% of
maximal test-compound inhibitory capacity.
Equations 5 and 6 are then combined in Eq. 7 describ-
ing the TNFa-response in the central R and peripheral Rt
compartments.
dR
dt
¼ SðS3Þ  IðCpÞ  koutR þ kt  Rt  Rð Þ
dRt
dt
¼ kt  ðR  RtÞ
ð7Þ
Smax is the maximum stimulatory capacity, SC50 concen-
tration of S3 at 50% of maximum stimulation, c a Hill
exponent, Imax maximum inhibitory capacity by test com-
pound and IC50 test compound potency. Neither S1, S2 or
S3, nor TNFa-response display any baseline concentrations
in the proposed model. Without any stimulation from LPS
there is no TNFa-response to inhibit with test compound.
The determinants of the TNFa-response at equilibrium
are given by Eq. 8.
Req ¼ 1
kout
 SðS3Þ  IðCpÞ
¼ 1
kout
 Smax  S
c
3
SC
c
50 þ Sc3
 1 Imax  Cp
IC50 þ Cp
 
ð8Þ
This expression is presented as a 3D-plot in Appendix 2
using the final parameter estimates from regressing TNFa
response time data.
Data analysis
Non-linear mixed-effects modelling (NLME) [13] was
used to regress the model in Fig. 3 to TNFa-response data
and to capture inter-individual variability (IIV). The
number of animals was small (18 and 17 subjects in Study
1 and 2, respectively). Therefore, the IIV estimation was
restricted to Vmax, kLPS, SC50, kout, Imax and IC50 (See
Appendix). Residual variance of compound exposure was
modelled with an additive error model on the log-scale and
for response concentrations with a proportional error
model.
Model parameters were estimated using Monolix [20],
including stochastic approximation for the determination of
standard errors. In step 1, parameters in Eqs. 3–5 and 7
were based on TNFa-responses from Study 1. The phar-
macokinetic parameters in Eqs. 1 and 2 were estimated
from test compound data from Study 2. The pharmacoki-
netic parameters were then fixed together with systems
parameters from Step 1, and Imax and IC50 were estimated
from Study 2 data. Further computational details can be
found in Appendix 1.
Results
Experimental data
Figure 4 shows the plasma concentration–time course of
test compound (left) and dose-normalized plasma concen-
trations (right). The exposure to test compound increases
disproportionately with increasing doses of test compound,
which suggests nonlinear elimination with increasing oral
doses. There is also a weak tendency of a longer terminal
half-life with increasing oral doses. This nonlinearity was
captured by Eq. 1.
The TNFa-response following three different intra-
venous LPS challenge doses of 3, 30 and 300 lgkg-1 is
shown in Fig. 5. TNFa data display a 30 min time-delay in
onset of response independently of challenge dose (Fig. 5
left). Additionally, TNFa-response time courses show a bi-
phasic post-peak decline (Fig. 5 right). This motivated the
two-compartment structure for the TNFa-response.
The areas under the TNFa-response time curves are
plotted versus LPS challenge dose in Fig. 6 (left, Study 1),
as are the areas under the TNFa-response time at a fixed
LPS challenge dose of 30 lgkg-1 but increasing test
compound doses of 0.3, 3 and 30 mgkg-1 (right, Study 2).
The exploratory analysis shows that both increasing LPS
doses and increasing test compound doses have an opposite
nonlinear impact on the TNFa response.
Figure 7 shows TNFa response versus test compound
concentrations for the fixed 30 lgkg-1 LPS challenge and
three test compound interventions (0.3, 3 and 30 mg kg-1
Compound A, Study 2) superimposed on the peak TNFa
response range (horizontal red dashed lines) of 30 lgkg-1
LPS challenge (Study 1). There is a 50% reduction in TNFa
peak response already at the lowest test compound dose,
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suggesting that efficacious test compound concentrations
fall within the 10–100 nM range.
The TNFa model is mathematically described by
Eqs. 1–7. The first-order input and Michaelis–Menten-
output were obtained from separately regressing concen-
tration-time data of test compound. A biophase compart-
ment was included to mimic the time courses of LPS in
plasma. The 30 min LPS dose-independent time delay of
TNFa-response was captured by simultaneously combining
a series of transit compartments with a nonlinear stimula-
tory term of transit compartment S1. The latter varied
between zero and unity and allowed the same time of onset
of action for the TNFa-response for all LPS doses. The
intensity of TNFa-response showed saturation with
increasing LPS doses. This was modelled by means of a
nonlinear stimulatory function with its own LPS-potency
Fig. 4 Left: semi-logarithmic plot of concentration–time data of test-
compound A at three oral doses (0.3, 3 and 30 mgkg-1, shown as
dotted, dashed and solid lines, respectively) in Sprague–Dawley rats
from Study 2. Test compound was administered 2 h before
intravenous challenge with LPS. The dashed red horizontal line
represents the model-predicted test compound potency of about
20 nM. Right: Dose-normalized test compound concentrations plotted
versus time
Fig. 5 Left: TNFa-response time courses at increasing intravenous
LPS challenge (3, 30 and 300 lgkg-1 LPS, shown as dotted, dashed
and solid lines, respectively) in Sprague–Dawley rats from Study 1.
The blue horizontal double arrow represents the initial time delay in
onset of response, and the red vertical double arrow, the 20–80 range
in TNFa peak-response of the 30 lgkg-1 LPS challenge. Right:
Semi-logarithmic plot of the same TNFa-response time courses
(Color figure online)
Fig. 6 Left: Area under the
TNFa-response plotted versus
increasing LPS challenge doses
(3, 30 and 300 lgkg-1 LPS)
from Study 1. Right: Area under
the TNFa-response plotted
versus increasing oral doses of
test compound (0.3, 3 and
30 mgkg-1 test-compound A)
and a fixed intravenous LPS
challenge with 30 lg kg-1 from
Study 2
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parameter SC50, driven by the last transit compartment S3.
The bi-phasic post-peak decline of TNFa-response was
captured by means of a two-compartment (central R and
peripheral Rt) model. TNFa-response time data of Study 1
were regressed after increasing LPS challenge doses (3, 30
and 300 lgkg-1 LPS). Regression of TNFa-response time
data of Study 2 after increasing oral test compound doses
(0.3, 3 and 30 mgkg-1 Compound A) with a fixed intra-
venous LPS challenge (30 lgkg-1) was then done as a last
step to get potency IC50 and maximum inhibitory capacity
Imax of test compound.
Model regression
TNFa during LPS challenge: study 1
Equations 3 and 4 captured the TNFa-response at all LPS
challenges (Fig. 8) and revealed system properties (such as
kt, kout) and challenge characteristics (such as ks, kLPS,
Km, LPS, Smax, SC50). Future selection of potential drug
candidates may focus the estimation on potency and effi-
cacy applying the selected framework while keeping sys-
tem fixed.
Experimental data show a 30 min time lag in onset
coupled to a slight peak-shift in TNFa-response at
increasing LPS doses, which suggests a nonlinear stimu-
lation of TNFa release. The final parameter estimates and
their precision (CV%) are shown in Table 3. The predicted
half-life of TNFa-response was less than 10 min. The
elimination rate constant of LPS from the biophase com-
partment, the transit compartment rate constant and the
fractional turnover rate of TNFa-response were all short
and fell in the same range (with half-lives of 5, 13 and
7 min, respectively).
TNFa during a fixed LPS challenge coupled to varying test
compound intervention: study 2
The exposure to test-compound A was well characterized
by Eqs. 1, 2 (Fig. 9 left). Test compound was given 2 h
prior to the LPS challenge dose (30 lgkg-1). The model-
predicted test compound concentration peaked within an
hour at the lowest dose (0.3 mgkg-1), consistent with
experimental data. A peak shift was then observed in
model predictions due to the capacity-limited elimination
with increasing doses of test compound (at 3, 30 mgkg-1).
Fig. 7 Hysteresis plot of individual TNFa-response plotted versus A
concentrations following a fixed intra-venous LPS challenge dose
(30 lgkg-1) and increasing oral doses of test-compound A (0.3, 3
and 30 mgkg-1). The upper and lower dashed horizontal lines
represent the TNFa peak response range in vehicle control animals
given only a 30 lgkg-1 LPS challenge dose (Study 1)
Fig. 8 Observed concentrations (red dots) and predicted response
time courses (solid lines) of TNFa-response for all subjects in Study 1.
LPS challenge was 3 lgkg-1 (upper), 30 lgkg-1 (middle) and
300 lgkg-1 (lower) (Color figure online)
230 Journal of Pharmacokinetics and Pharmacodynamics (2019) 46:223–240
123
All pharmacokinetic parameters and their precision were
well characterized (Table 4).
The model captured all features (such as onset, intensity
and duration) of the TNFa-response at a fixed LPS chal-
lenge (30 lgkg-1) and varying test compound doses
(Fig. 9 right). A slight leftward shift in TNFa peak
response was observed for increasing test compound doses.
The final test compound parameters of Imax and IC50 are
shown in Table 5. Test compound displayed partial inhi-
bition (Imax = 0.675 or 68%) of LPS-induced TNFa-re-
sponse, and a corresponding potency of about 20 nmolL-1
Table 3 Final
pharmacodynamic model
estimates, their CV% and IIV
and IIV CV% as well as
resulting half-life
Parameter Units Final estimate CV% IIV% IIV CV% Half-life (min)
kLPS h
-1 8.36 29 30.4 19 5
ks h
-1 3.28 8.1 – – 13
Km, LPS lgkg-1 0.0789 19 – –
Smax ngL-1h-1 6105 12 – –
SC50 – 0.469 14 9.0 42
c – 3.79 2.5 – –
kout h
-1 5.65 30 14.8 34 7
kt h
-1 0.419 37 – – 100
Fig. 9 Left column: Observed (red dots) and model-predicted (solid
lines) concentration–time data of test compound (A) of all subjects in
Study 2. Right column: Observed (red dots) and model-predicted
(solid lines) TNFa-response data of all subjects in Study 2. TNFa-
response was observed after a fixed LPS challenge of 30 lgkg-1.
Test compound doses were 0.3 mgkg-1 (upper row), 3 mgkg-1
(middle row), and 30 mgkg-1 (bottom row) (Color figure online)
Journal of Pharmacokinetics and Pharmacodynamics (2019) 46:223–240 231
123
(IC50 = 23.1 nM) as total plasma concentration of test
compound A.
Between-subject variability and residual uncertainty
The inter-individual variability in TNFa-response (Study 1)
is well predicted in the 3 and 30 lgkg-1 dose groups
(Fig. 10 left and middle). The inter-individual variability in
TNFa-response is also well predicted in the 0.3 mgkg-1
test compound dose group (Fig. 11 lower left). Variability
is overestimated in the 3 and 30 mgkg-1 dose group
(Fig. 11 lower middle and right).
Model simulations
Model simulations were done with a fixed test compound
dose (3 mgkg-1) and increasing LPS challenges (Fig. 12,
upper row) in order to clarify the behavior of the model.
Predictions show suppression of TNFa peak response
proportional to LPS challenge, as well as a peak-shift in
TNFa-response with increasing LPS doses. Model simula-
tions were also performed with a fixed challenge dose
(30 lgkg-1) and varying test compound doses (0.03, 0.3
and 3.0 mgkg-1) (Fig. 12, bottom row). Approximately
70% suppression was observed in TNFa-response with the
3.0 mgkg-1 dose since Imax was estimated to 0.675. The
model-predicted in vivo potency IC50 of test compound is
20 nM (Table 3), which is consistent with experimental
data. The test compound exposure covers a 10 to 1000 nM
concentration range, which brackets the potency estimate.
Discussion
A mechanism-based model describing TNFa-response was
fitted to data obtained after several LPS challenges alone
(Study 1) and a fixed LPS challenge in combination with
varying doses of test compound (Study 2). The model
captured experimental data well and gave accurate and
precise parameters. ‘‘What-if’’ predictions were then made
to explore model behavior at a fixed test compound dose
and varying LPS challenges, and the reverse scenario. This
was done to further evaluate the combined impact of test-
compound and LPS challenge on the time course of TNFa
with respect to lag-times, peak-shifts and duration
response.
Experimental data
Test compound is a phosphodiesterase 4 PDE4 inhibitor,
which indirectly targets mechanisms responsible for TNFa
release. This requires the compound to be present during
LPS challenge, since it does not affect circulating TNFa,
Table 4 Final pharmacokinetic
estimates, their CV% and IIV
and CV%
Parameter Units Final estimate CV% IIV% (CV %) IIV CV%
ka h
-1 1.72 12 – –
Vp Lkg-1 3.30 4.2 – –
Vmax lmolh-1kg-1 32.2 14 11.5 22
Km lmolL-1 18.2 16 – –
Table 5 Final pharmacodynamic model estimates, their CV% and
IIV and IIV CV%
Parameter Units Final estimate CV% IIV% IIV CV%
Imax – 0.675 5 25.1 68
IC50 nmolL-1 23.1 26 24.5 127
Fig. 10 Visual predictive checks for the TNFa-response during LPS
challenge (Study 1). Solid black symbols correspond to model-
predicted time courses. The shaded grey areas show variability in
predicted time courses. Dashed lines show the 5% (lower) and 95%
(upper) percentiles and the middle solid line is the median. LPS
challenge was 3 lgkg-1 (left), 30 lgkg-1 (middle) and 300 lgkg-1
(right)
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Fig. 11 Semi-logarithmic plot of test compound exposure and TNFa-
response (Study 2). Upper row: Visual predictive check of test
compound concentration. Lower row: Visual predictive check of
TNFa-response at 30 lgkg-1 LPS challenge and varying test
compound intervention. Filled circles correspond to model-predicted
time courses for test-compound concentration and TNFa-response,
respectively. The shaded grey areas are the predicted variability.
Dashed lines show the 5 to 95% percentiles and solid line the median.
Test compound doses were 0.3 mgkg-1 (left column), 3 mgkg-1
(middle column) and 30 mgkg-1 (right column)
Fig. 12 Upper row: Impact of different LPS doses (3, 30,
300 lgkg-1) on TNFa-response given with (solid lines) and without
(dashed line) 3 mgkg-1 of test compound. Bottom row: Impact of a
fixed LPS dose (30 lgkg-1) on TNFa-response with (solid lines) and
without (dashed lines) changing test compound doses (0.03, 0.3 and
3.0 mgkg-1). The red vertical dashed lines show the peak-time
locations (Color figure online)
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which has been shown previously. Test compound
demonstrates partial inhibition of TNFa release. Experi-
mental data of test compound exposure were lacking prior
to Cmax with a predicted tmax at about 1 to 2 h (Fig. 9).
The biological mechanism behind LPS challenge on
TNFa release was described previously [23], and a model
was therefore constructed to capture that behavior (Fig. 2).
Saturable stimulation of TNFa release was seen for the
0.3–30 lgkg-1 LPS dose range (Fig. 6 left), which is also
supported by other studies [9]. There seems to be a fixed
time-delay in the onset of TNFa-response of approximately
30 min after the LPS challenge (Fig. 5), which suggests a
saturable stimulatory effect of LPS. Similar studies
[6, 10–12] have also captured the time-delay before onset
of TNFa-response in plasma. Low variability was seen in
exposure to test compound, which was captured by the
model (Fig. 8 left and Fig. 10 upper row).
Following onset of TNFa-response, the rise of TNFa
occurred rapidly (Fig. 5 left) and displayed a peak-shift
with increasing LPS challenge (Fig. 11 upper row). The
rapid rise and decline of TNFa indicates a high turnover.
The extent of drug exposure will then govern the duration
of TNFa-response. The current mechanism of action will
not allow sufficient inhibition of TNFa release in acute
treatment. Both transcriptional and post-transcriptional
mechanisms related to test compound [8, 9] have been
suggested to influence the TNFa release.
Model regression
Acute cytokine release has previously been modeled with
discontinuous functions, allowing the induced formation of
TNFa to take place only for a defined period [10–12, 24].
Others have used a continuous model as stimulatory
function coupled to transit compartments [6]. However, the
present design revealed that following a dose-independent
time-delay of 30 min, rapid onset of response and saturable
intensity was observed in the TNFa-response. The intensity
of response was then followed by a bi-phasic terminal
decline in TNFa-response. The bi-phasic decline was cap-
tured by a 2-compartment TNFa-response model (Fig. 2).
A multi-phasic decline of TNFa-response coupled to
rebound after LPS provocations has also been reported for
primates [6]. In contrast to the primate study, no rebound
was seen in TNFa-response in Sprague–Dawley rats.
The estimated fractional turnover rate of TNFa is
5.65 h-1 in Sprague–Dawley rats, which is consistent with
0.5–4.51 h-1 in mice, 10 h-1 in cynomolgus monkeys and
1.82 h-1 in humans [6, 10–12, 24, 28]. This suggests a fast
turnover or short half-life of TNFa in all studied species so
far. The transfer rate ks was estimated to about 3.3 h
-1,
which leads to a delay of peak stimulation of about 1.2 h
(Figs. 8 and 9 right). Previously published data support
this, reporting TNFa peak concentrations between 1 and
2 h after LPS administration, independently of species
[6, 10–12, 24].
The Michaelis–Menten constant of test compound
clearance was predicted to be 20 lM (18.2 lmolL-1,
Table 4), which is 1000-fold higher than its potency IC50
(Table 5). Test compound exposure in the 30 mgkg-1
highest group barely reached 20 lM but stayed close to
10 lM for about 2 h before starting the decline at a slower
rate than in the low dose (0.3 mgkg-1 A) group. The
Michaelis–Menten equation suggests that saturation of
elimination is occurring and mechanistically this might be
due to saturation of drug-metabolizing enzymes and/or
drug transporter.
Physiologically, there is no observable baseline con-
centration of TNFa in blood. The cytokine is only released
into blood from activated monocytes in response to an
immunological stimulus [29]. The drug-induced inhibition
acts on the LPS stimulatory function S(LPS).
The model estimated test compound potency IC50 is
about 20 nM (0.0231 lmolL-1, Table 5) which is con-
sistent with the exploratory data on TNFa-response
(Fig. 7). The importance of also incorporating a vehicle
control group improves the assessment of how inter-occa-
sion variability may impact, for example, potency and
efficacy assessment in highly variable data. Ideally, all
substudies should contain vehicle control group(s). The
final estimate of Imax suggests that there is a partial
reduction in TNFa-response of 70% at the highest test-
compound dose of 30 mgkg-1.
We would also like to highlight the importance of
actually measuring the challenger as such, rather than
making indirect inferences about its behavior via a bio-
phase model [6]. LPS exposure data would be helpful in
future studies to examine whether the inter-individual
variability observed in TNFa-response is explained by a
variable LPS exposure or not. The uncertainty in the actual
LPS exposure will indirectly inflate how accurate and
precise the drug parameters, such as IC50 and Imax, are
estimated.
Vehicle control data (combined with test compound
dose 0 mgkg-1) of TNFa-response were lacking in Study
2. Therefore, fixed final parameter values of system prop-
erties (Study 1) were used to facilitate the regression of test
compound specific Imax and IC50 parameters of Study 2. A
crossover design measuring TNFa-response following the
same LPS challenge with or without drug intervention in
each subject may be considered in future designs.
Model simulations
Model simulations were done with a fixed test compound
dose (3 mgkg-1) and increasing LPS challenges (Fig. 11,
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upper row) in order to illuminate the determinants of onset,
intensity and duration of TNFa-response. Predictions show
suppression of TNFa peak response proportional to LPS
challenge, as well as a peak-shift in TNFa-response with
increasing LPS doses. Model simulations were also per-
formed with a fixed challenge dose (30 lgkg-1) and
varying test compound doses (0.03, 0.3 and 3.0 mgkg-1)
(Fig. 11, bottom row). Approximately 70% suppression
was seen in TNFa-response with the 3.0 mgkg-1 dose
because Imax was estimated to 0.675. Model-predicted
in vivo potency IC50 of test compound is 20 nM (Table 3),
which is consistent with experimental data. The test com-
pound exposure covers the 1.0 to 100 nM concentration
range, which brackets the potency estimate. Multiple LPS
challenges demonstrated a peak-shift in TNFa-response
with increasing doses.
LPS exposure should, if possible, be incorporated into
future studies to handle the origin of variability seen in
TNFa response. Information about the onset, intensity and
duration of TNFa response upon LPS challenge and/or test
compound intervention may be improved by higher reso-
lution of experimental TNFa response data at pivotal time
points [6]. Repeated (sparse) sampling of TNFa response in
the same individual after LPS or test compound interven-
tion is still recommended. Table 6 contains a summary of
major findings related to the pharmacodynamic time course
and suggested improvements of future designs of TNFa
response as a biomarker. Table 7 is an attempt to sum-
marize some general points to consider related to topics
such as potency, experimental design and target biology.
Overall conclusion
A mechanism-based biomarker model of TNFa-response,
including different external provocations of LPS challenge
and test compound intervention, was developed to serve as
a modelling tool. The model contained system properties
(such as kt, kout), challenge characteristics (such as ks, kLPS,
Km, LPS, Smax, SC50) and test- compound-related parameters
(Imax, IC50). The exposure to test compound was modelled
by means of first-order input and Michaelis–Menten type of
nonlinear elimination. Test compound potency was esti-
mated to 20 nM with a 70% partial reduction in TNFa-
response at the highest dose of 30 mgkg-1. Future selec-
tion of drug candidates may focus the estimation on
potency and efficacy applying the selected structure con-
sisting of TNFa system and LPS challenge characteristics.
A related aim was to demonstrate how an exploratory
(graphical) analysis may guide us to a tentative model
structure, which enables us to better understand target
biology. The analysis demonstrated how to tackle a bio-
marker with a baseline below the limit of detection.
Repeated LPS-challenges may also reveal how the rate and
extent of replenishment of TNFa pools occur. Lack of LPS
exposure-time courses was solved by including a biophase
model, with the underlying assumption that TNFa response
time courses as such contain kinetic information. A trans-
duction type of model with non-linear stimulation of TNFa
release was finally selected. Typical features of a challenge
experiment were shown by means of model simulations.
Experimental shortcomings of present and published
designs were identified and discussed. The final model
coupled to suggested guidance rules may serve as a general
basis for the collection and analysis of pharmacological
challenge data of future studies.
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Appendix 1
Principal parts of the model
The model described in Eqs. 1–7 was formulated based on
five central observations in data, namely (1) LPS dose-
independent delay of onset of TNFa-response; (2) LPS
dose-dependent duration of TNFa-response; (3) LPS chal-
lenge has a saturable stimulatory impact on the TNFa-re-
sponse; (4) test compound has a saturable inhibitory impact
on the TNFa-response; (5) TNFa-response declines in a bi-
phasic fashion post-peak.
The onset of TNFa-response was delayed about 30 min
independently of LPS challenge dose (Fig. 5, left). The
combination of a time-limited constant input signal,
transportation through a chain of delay compartments and a
nonlinear (sigmoid) stimulatory function captures data
nicely for all LPS challenges. Using a first-order input/
output biophase model for the LPS kinetics (Eq. 3;
Fig. 13a) combined with a saturable stimulatory function
(Eq. 4; Fig. 13b) gave constant time-limited stimulatory
input of TNFa. Higher LPS doses will increase the time
during which the input signal is totally saturated, which
explains the LPS dose-dependent duration of TNFa-re-
sponse. This input signal is transported through a series of
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transduction compartments (Eq. 4; Fig. 13c), which
explains the delay of onset of TNFa-response. Stimulation
of TNFa release is then captured by means of a saturable
function (Eq. 5; Fig. 13g), which explains the rapid onset
of TNFa-response.
The saturable stimulatory impact of LPS challenge on
TNFa-response is summarized in Fig. 6 (left), which is
described by Eq. 5. Increasing the dose of test-compound
had a nonlinear inhibitory effect on TNFa-response (Fig. 6,
right), which is captured by Eq. 6. The post-peak bi-phasic
Table 6 Summary of major findings and suggested improvements for future designs
Study Points to
consider
Major findings Suggested improvement of design
1 Delay after LPS
dose
Constant delay of 30 min independently of LPS dose Sampling of systemic LPS exposure. Design(s) for
understanding your target. Apply a biophase model of LPS
exposure
1 Peak-shifts in
TNFa-
response
Peak-shifts in TNFa-response seen with increasing
doses of LPS
Sampling of systemic LPS exposure, which may explain
some of the peak-shift in TNFa-response
1 Assessment of
saturation of
response
Saturation of TNFa-response at higher LPS doses
assessed from dose-normalized TNFa-response time
courses
Sampling of systemic LPS exposure, which may explain
some of the saturation observed in TNFa-response
2 Baseline
response
Vehicle control group was lacking in Study 2 to assess
the impact of LPS challenge on TNFa-response
Sampling of systemic LPS exposure. Use cross-over design
for determination of LPS-induced TNFa-response with and
without test compound
2 Delay after test
compound
dose
Delay in onset of TNFa-response upon drug
intervention is not observed
Allow higher granularity of test compound exposure
2 Peak-shifts No peak-shifts were seen in LPS induced TNFa-
response with increasing test compound doses
Sampling of systemic LPS exposure, which may explain
lack of peak-shift in TNFa-response with increasing test
compound doses
2 Saturation of
response
A maximum inhibitory effect of test compound was
obtained in the TNFa-response at an LPS challenge
dose of 30 lgkg-1
Sampling of systemic LPS exposure, which may explain
some of the saturation observed in TNFa-response with
increasing test compound doses
Table 7 Points to consider when modelling cytokine challenge test data
Topic Points to consider
General High interest in modelling challenge test data, but a robust quantitative approach is still in its infancy. More diverse datasets
and models are needed
Potency Drug screening and clinical efficacy are primarily driven by in vitro and ex vivo whole-blood (WB) assays where cytokine
release is measured after LPS challenge in vitro. The primary questions relate to the predictive power of WB assays. What is
the role of blood-born versus tissue-born cells? The in vivo/in vitro correlation IVIVC may give some guidance with respect
to potential clinical outcome, where only WB is available at an early stage. The IVIVC with respect to biochemical target
may also exclude off-target effects
IC50 is approximately 20 nM. In vivo potency is a conglomerate of binding (affinity, koff and kon), target turnover (kdeg) and
ligand-target complex kinetics (ke(RL)) [32, 33]. This new expression enables a more efficient species-to-species comparison
of pharmacodynamic properties. Imax gives insight about whether full or partial TNFa suppression is possible (tissues
responding to LPS but lacking the target)
Study design The TNFa-response is rapid and transient, which is a challenge in experimental design. Small time-differences may result in
large baseline observations, and therefore cause erroneous assessment of drug inhibition. This is an argument against single
(end) point studies and favor biomarker time courses. Vehicle control groups should be included in all substudies
Target biology Can a mechanism-based model cast light on LPS acting on precursor pool-driven release of TNFa (post-translational effects) or
mRNA-driven induction (transcriptional effects)? The onset of TNFa release is rapid, suggesting post-translational
mechanisms. Can better insight be accomplished (depletion of precursor pool/efficacy after repeated dosing)? Is there a risk of
tachyphylaxia with either mechanism?
Dosing
regimens
Is the drug mechanism curative or prophylactic? If prophylactic, how should the dose be given optimally, and what are the
pharmacokinetic requirements? What is the translational potential of the model across species? Are human systems
parameters predictable from animal data?
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Fig. 13 Presentation of time courses and auxiliary relationships in the
model for a single subject after LPS challenge (30 lgkg-1) and test-
compound administration (3 mgkg-1). Blue labels mark concentra-
tion–time courses, whereas red labels mark relationships between
different quantities in the model. LPS biophase concentration is
shown in plot a, the time-dependent stimulation of signal compart-
ment S1 in plot b and the concentrations in the three signal
compartments S1 to S3 in plot c. In plots d and e, showing response
and test compound concentration, observed data is included. Plot
f shows the relationship of concentration in the LPS biophase and the
stimulation of signal compartment S1. In plots g and h the stimulation
and inhibition of the TNFa-response are shown over concentration in
compartment S3 and drug concentration Cp, respectively (Color
figure online)
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decline in TNFa-response (Fig. 5, right) was modelled by
inclusion of a peripheral response compartment Rt (Eq. 7).
Computational details
Parameter selection for NLME modelling
To determine which parameters had a large influence on
the model-predicted TNFa concentration, a variance-based
sensitivity analysis was conducted using the Sobol method
[14]. The Python (Python Software Foundation, https://
www.python.org, version 3.6) package SALib [15] was
used for this analysis. Additionally, complementary roles
of parameters (e.g. Smax and SC50 both influence peak
TNFa concentration) were considered and parameters
exhibiting larger IIV during test runs were preferred when
deciding what parameters to associate with IIV or not for
NLME modelling. Both Imax and IC50 were of great interest
in this study and were therefore modelled with IIV.
Resulting from this analysis, the following distributions
were assigned to parameters: Vmax (Eq. 2) normally dis-
tributed, kLPS (Eq. 3), SC50 (Eq. 5) and kout (Eq. 7) and
IC50 (Eq. 6) log-normally distributed, and Imax (Eq. 6)
logit-normally distributed. No correlations between ran-
dom effects were included in the model.
Identifiability analysis
A basic prerequisite for parameter estimation of a complex
model is for the model to be structurally identifiable, given
observed variables. Structurally identifiable means that any
two distinct sets of parameters of a model will not result in
identical observations, i.e., parameter values are uniquely
determined by observed data. The model Eqs. 1–7 were
checked for local structural identifiability using the Exact
Arithmetic Rank (EAR) algorithm [16–18]. The Wolfram
Mathematica (Wolfram Research Inc., Version 11.1)
package IdentifiabilityAnalysis (see Karlsson et al. [17] for
a theoretical description; implemented at the Fraunhofer-
Chalmers Centre) was used for this analysis. The basic
EAR algorithm requires the model equations to be rational
functions. However, a larger class of system can be
addressed by EAR by transformations demonstrated in
Reference [19].
Model and convergence checking
Parameter convergence was assessed by repeated estima-
tion using different initial values for parameters leading to
sets of parameter estimates in close proximity to each
other. Standard errors, derived from a stochastic approxi-
mation of the Fisher information matrix, were as low as
possible. Individual parameters were simulated from the
conditional parameter distribution and statistical parameter
models were checked by comparison of simulated indi-
vidual parameters to the theoretical distributions [21].
Model fit was assessed through the investigation of indi-
vidual and population residuals and their distributions as
well as visual predictive checks [22].
Appendix 2
Contributions from inflammation and drug
intervention at equilibrium
Model simulations using Eq. 8 showing the joint impact of
exposure (Cp) and LPS stimuli (S3) on TNFa-response
(left), and exposure (Cp) and biophase amount of LPS
(ALPS) on TNFa-response (right).
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